Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kaletra (ABT-378/r) approved.

J S James

    AIDS Treatment News
    |August 14, 2002
    PubMed
    Summary

    Kaletra, a combination of lopinavir and ritonavir, is a new protease inhibitor. This summary provides details and information sources on its approval and use.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ability of palatable food consumption to buffer against the short- and long-term behavioral consequences of social defeat exposure during juvenility in rats.

    Physiology & behavior·2017
    Same author

    Effects of electroconvulsive seizures on depression-related behavior, memory and neurochemical changes in Wistar and Wistar-Kyoto rats.

    Progress in neuro-psychopharmacology & biological psychiatry·2014
    Same author

    The effects of rewarding ventral tegmental area stimulation and environmental enrichment on lipopolysaccharide-induced sickness behavior and cytokine expression in female rats.

    Brain research·2008
    Same author

    Behavioral and physiological effects of a single injection of rat interferon-alpha on male Sprague-Dawley rats: a long-term evaluation.

    Brain research·2006
    Same author

    Testosterone cream available at CPS; gel approved by FDA.

    AIDS treatment news·2003
    Same author

    Fluconazole: Pfizer asked to lower Africa price.

    AIDS treatment news·2003

    Area of Science:

    • Pharmacology
    • Infectious Diseases

    Background:

    • Kaletra (lopinavir/ritonavir) is a newly approved protease inhibitor.
    • This medication is indicated for specific therapeutic uses.

    Discussion:

    • The abstract provides essential details regarding Kaletra.
    • Information sources for further research are included.

    Key Insights:

    • Kaletra represents a significant advancement in protease inhibitor therapy.
    • Understanding its properties and applications is crucial for healthcare professionals.

    Outlook:

    • Further clinical data and real-world evidence will shape the future use of Kaletra.
    • Ongoing research will explore its efficacy and safety profile.